Morepen Laboratories profit drops 20% on flat revenue
Consolidated net profit fell to ₹94.88 crore for FY26 as margin pressure weighed on the bottom line. The board recommended a dividend of ₹0.20 per share.
— 4 earlier stories on Morepen Laboratories Ltd. →What's new
- Consolidated net profit fell 19.6% to ₹94.88 crore.
- Revenue from operations stayed flat at ₹1,805.69 crore.
- The medical devices business transfer date moved to April 1, 2026.
Why this matters
Flat revenue paired with a double-digit profit decline signals rising costs that the company failed to pass on. The standalone profit drop of 35% is particularly sharp, suggesting the core business is facing more strain than the consolidated figures imply.
What we're watching
- Whether margins recover in the coming quarters.
- The impact of the medical devices business transfer on future earnings.
- Management commentary on the cost pressures behind the profit decline.
The full read
Morepen Laboratories closed FY26 with a 19.6% decline in consolidated net profit, hitting ₹94.88 crore against ₹118.02 crore in the prior year. Revenue remained stagnant at ₹1,805.69 crore, indicating that margin compression is the primary driver of the earnings slump. The standalone performance was even weaker, with profit dropping 35% to ₹66.06 crore. Amid these results, the board recommended a final dividend of ₹0.20 per share and pushed the effective date for the transfer of its medical devices business to its subsidiary, Morepen Medipath, to April 1, 2026. While the auditor provided a clean, unmodified opinion on the financials, the disconnect between flat top-line growth and falling profitability remains the central challenge for the company. The shift in the business transfer date is a procedural update, but the underlying margin pressure is the real story here.
Questions answered
- How did Morepen's profit perform compared to the previous year?
- Consolidated net profit fell 19.6% to ₹94.88 crore for the year ended March 2026, down from ₹118.02 crore in the prior year.
- What was the revenue trend for the year?
- Revenue from operations remained nearly flat at ₹1,805.69 crore.
- What is the status of the medical devices business transfer?
- The board amended the appointed date for transferring the medical devices business to its subsidiary, Morepen Medipath, to April 1, 2026.
- Did the auditor raise any concerns?
- No, the auditor issued unmodified opinions on both the standalone and consolidated financial results.
Story so far
All notes on MOREPENLAB →- 26 May 2026 · 5:38 PM IST Morepen Laboratories profit drops 20% on flat revenue
- today Morepen Laboratories profit jumps 69% as CDMO production kicks off
- 1d ago Morepen Laboratories profit drops 20% as margins tighten
- 1d ago Morepen Laboratories reports 20% profit decline for FY26
- 7d ago Morepen locks in medical devices chief with subsidiary shares